Drug Delivery Across the Blood-Brain Barrier

Comprehensive Biotechnology, Second Edition

Volumn 5, Issue , 2011, Pages 657-667

  Lalatsa, A ^a   Schatzlein A G ^a   Uchegbu, I F ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Blood brain barrier; Central nervous system; Delivery strategies; Drug modification; Lipidization; Nanoparticles; Nasal delivery; Oral delivery; Transporters

Indexed keywords

EID: 85012825432     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-08-088504-9.00180-X     Document Type: Chapter

References (30)

1. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006, 3(11):e442.
2. Begley D.J. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. Journal of Pharmacy and Pharmacology 1996, 48(2):136-146.
3. Gleeson M.P. Generation of a set of simple, interpretable ADMET rules of thumb. Journal of Medicinal Chemistry 2008, 51(4):817-834.
4. Abbott N.J., Patabendige A.A., Dolman D.E., et al. Structure and function of the blood-brain barrier. Neurobiology of Disease 2010, 37(1):13-25.
5. Broadwell R.D., Balin B.J., Salcman M. Transcytotic pathway for blood-borne protein through the blood-brain barrier. Proceedings of the National Academy of Sciences of the United States of America 1988, 85(2):632-636.
6. Herve F., Ghinea N., Scherrmann J.M. CNS delivery via adsorptive transcytosis. AAPS Journal 2008, 10(3):455-472.
7. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. Journal of Neurochemistry 2004, 89(4):807-811.
8. Schlageter K.E., Molnar P., Lapin G.D., Groothuis D.R., et al. Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvascular Research 1999, 58(3):312-328.
9. Vandergrift W.A., Patel S.J., Nicholas J.S., Varma A.K., et al. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurgical Focus 2006, 20(4):E13.
10. Fung L.K., Ewend M.G., Sills A., et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Research 1998, 58(4):672-684.
11. Sakane T., Tanaka C., Yamamoto A., et al. The effect of polysorbate 80 on brain uptake and analgesic effect of D-kyotorphin. International Journal of Pharmaceutics 1989, 57:77-83.
12. Borlongan C.V., Emerich D.F. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: Laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Research Bulletin 2003, 60(3):297-306.
13. Mesiwala A.H., Farrell L., Wenzel H.J., et al. High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound in Medicine and Biology 2002, 28(3):389-400.
14. Hynynen K. Ultrasound for drug and gene delivery to the brain. Advanced Drug Delivery Reviews 2008, 60(10):1209-1217.
15. Takada Y., Greig N.H., Vistica D.T., et al. Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier. Cancer Chemotherapy and Pharmacology 1991, 29(2):89-94.
16. Polt R., Porreca F., Szabo L.Z., et al. Glycopeptide enkephalin analogues produce analgesia in mice: Evidence for penetration of the blood-brain barrier. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(15):7114-7118.
17. Moos T., Morgan E.H. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. Journal of Neurochemistry 2001, 79(1):119-129.
18. Rebeck G.W., Reiter J.S., Strickland D.K., et al. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 1993, 11(4):575-580.
19. Yamamoto M., Ikeda K., Ohshima K., et al. Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. Cancer Research 1997, 57(13):2799-2805.
20. Regina A., Demeule M., Che C., et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. British Journal of Pharmacology 2008, 155(2):185-197.
21. Terasaki T., Hirai K., Sato H., et al. Absorptive-mediated endocytosis of a dynorphin-like analgesic peptide, E-2078 into the blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics 1989, 251(1):351-357.
22. Batrakova E.V., Vinogradov S.V., Robinson S.M., et al. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjugate Chemistry 2005, 16(4):793-802.
23. Bodor N., Prokai L., Wu W.M., et al. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 1992, 257(5077):1698-1700.
24. Pardridge W.M. shRNA and siRNA delivery to the brain. Advanced Drug Delivery Reviews 2007, 59(2-3):141-152.
25. Jiang C., Koyabu N., Yonemitsu Y., et al. In vivo delivery of glial cell-derived neurotrophic factor across the blood-brain barrier by gene transfer into brain capillary endothelial cells. Human Gene Therapy 2003, 14(12):1181-1191.
26. Troster S.D., Muller U., Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. International Journal of Pharmaceutics 1990, 61:85-100.
27. Vinogradov S.V., Batrakova E.V., Kabanov A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjugate Chemistry 2004, 15(1):50-60.
28. Qu X., Khutoryanskiy V.V., Stewart A., et al. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. Biomacromolecules 2006, 7(12):3452-3459.
29. Uchegbu IF, Schatzlein AG, and Lalatsa A (2010) Oral Delivery of Hydrophilic Drugs to the Brain. WO/2010/100479, 1 March 2010.
30. Novakovic Z.M., Leinung M.C., Lee D.W., Grasso P., et al. Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. Regulatory Peptides 2009, 154(1-3):107-111.